Jun 2026 (Q2 FY26) — Jul 29, 2026
Beta Bionics Q2 FY26 — Strong Revenue Growth and Pipeline Progress
Read the full callBeta Bionics (BBNX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Beta Bionics earnings: last reported Wed, 29 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 32.0 | +37.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -79.9 | +5.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -23.4 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$16.35 −5.55% · −$0.96
Performance −22.6% 1Y
1Y: $21.13 on 15 Oct 2025 → $16.35. High $31.99 (8 Jan 2026), low $8.86 (10 Apr 2026).
- Previous close
- $17.31
- 52-week range
- $8.86 – $31.99
- One year
- −20.75%
Overview
- Symbol
- BBNX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Beta Bionics earnings calls (BBNX)
Financials
What the filings say
Net profit, year on year: −39% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 17 | 20 | 18 | 23 | 27 | 32 | 28 | 32 |
| Operating profit | -11 | -13 | -19 | -20 | -17 | -16 | -24 | -26 |
| Operating margin | −65.7% | −63.8% | −105.7% | −85.5% | −62.5% | −50.2% | −87.9% | −79.9% |
| Other income | 1 | -5 | -10 | 3 | 3 | 3 | 2 | 2 |
| Net profit | -10 | -18 | -29 | -17 | -14 | -13 | -22 | -23 |
| EPS ($ per share) | -1.46 | — | -0.93 | -0.39 | -0.33 | — | -0.49 | -0.53 |
| Line item | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Equity capital | — | 0 | 0 |
| Reserves | -230 | -297 | -370 |
| Total liabilities | 51 | 74 | 41 |
| Fixed assets | 2 | 5 | 9 |
| Investments | 70 | 73 | 188 |
| Total assets | 110 | 150 | 329 |
| Line item | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Cash from operations | -32 | -48 | -51 |
| Cash from investing | -70 | -3 | -163 |
| Cash from financing | 101 | 56 | 215 |
| Net cash flow | -1 | 4 | 1 |
| Capital expenditure | -0 | -3 | -5 |
| Free cash flow | -33 | -52 | -56 |
Insider filings
70 filings between Oct 31, 2025 and Oct 1, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$4.54M
50 sales by 8 insiders
60% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 17
- Award — granted as compensation
- 3
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Hopman Mark | — | $1.60M | Oct 1, 2026 |
| Feider Stephen | — | $1.03M | Sep 2, 2026 |
| Saint Sean | — | $786.3K | Sep 3, 2026 |
| Mensinger Mike | — | $538.6K | Sep 16, 2026 |
| Jones Christy | — | $228.2K | Sep 22, 2026 |
| Russell Steven Jon | — | $176.7K | Sep 2, 2026 |
| Lezack Adam | — | $100.5K | May 22, 2026 |
| Palasis Maria | — | $79.4K | Dec 1, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Hopman Mark Chief Commercial Officer | Sale | 370 | $7.0K |
| Sep 22, 2026 | Jones Christy Director | Sale 10b5-1 plan | 6,430 | $147.9K |
| Sep 16, 2026 | Hopman Mark Chief Commercial Officer | Sale 10b5-1 plan | 30,779 | $619.6K |
| Sep 16, 2026 | Mensinger Mike Chief Product Officer | Sale 10b5-1 plan | 2,650 | $58.3K |
| Sep 14, 2026 | Hopman Mark Chief Commercial Officer | Sale 10b5-1 plan | 775 | $12.0K |
| Sep 9, 2026 | Hopman Mark Chief Commercial Officer | Sale 10b5-1 plan | 35,994 | $664.6K |
| Sep 3, 2026 | Saint Sean President & CEO | Sale 10b5-1 plan | 5,641 | $113.3K |
| Sep 2, 2026 | Hopman Mark Chief Commercial Officer | Sale | 5,327 | $101.8K |
| Sep 2, 2026 | Russell Steven Jon Chief Medical Officer | Sale | 4,221 | $80.7K |
| Sep 2, 2026 | Mensinger Mike Chief Product Officer | Sale | 4,375 | $83.6K |
| Sep 2, 2026 | Feider Stephen Chief Financial Officer | Sale | 6,675 | $127.6K |
| Sep 2, 2026 | Saint Sean President & CEO | Sale | 16,867 | $322.4K |
| Jun 29, 2026 | Feider Stephen Chief Financial Officer | Option exercise 10b5-1 plan | 4,896 | $25.0K |
| Jun 29, 2026 | Feider Stephen Chief Financial Officer | Sale 10b5-1 plan | 4,896 | $83.4K |
| Jun 26, 2026 | Feider Stephen Chief Financial Officer | Sale 10b5-1 plan | 5,104 | $87.0K |
| Jun 26, 2026 | Feider Stephen Chief Financial Officer | Option exercise 10b5-1 plan | 5,104 | $26.0K |
| Jun 24, 2026 | Hopman Mark Chief Commercial Officer | Sale 10b5-1 plan | 1,258 | $18.9K |
| Jun 24, 2026 | Jones Christy Director | Sale 10b5-1 plan | 1,406 | $21.1K |
| Jun 4, 2026 | Jones Christy Director | Sale 10b5-1 plan | 2,811 | $39.4K |
| Jun 4, 2026 | Hopman Mark Chief Commercial Officer | Sale 10b5-1 plan | 275 | $3.4K |
| Jun 2, 2026 | Saint Sean President & CEO | Sale | 16,872 | $212.7K |
| Jun 2, 2026 | Hopman Mark Chief Commercial Officer | Sale | 5,329 | $67.2K |
| Jun 2, 2026 | Russell Steven Jon Chief Medical Officer | Sale | 4,222 | $53.2K |
| Jun 2, 2026 | Feider Stephen Chief Financial Officer | Sale | 6,676 | $84.2K |
| Jun 2, 2026 | Mensinger Mike Chief Product Officer | Sale | 4,378 | $55.2K |
| May 22, 2026 | Lezack Adam Director | Sale 10b5-1 plan | 998 | $11.2K |
| May 21, 2026 | CARNEY SEAN Director | Award | 16,965 | $0 |
| May 21, 2026 | Jones Christy Director | Award 10b5-1 plan | 16,965 | $0 |
| May 21, 2026 | Jones Christy Director | Sale 10b5-1 plan | 1,998 | $19.9K |
| May 21, 2026 | Dearen Danny L. Director | Award | 16,965 | $0 |
| May 21, 2026 | Lezack Adam Director | Award 10b5-1 plan | 16,965 | $0 |
| May 21, 2026 | Lezack Adam Director | Sale 10b5-1 plan | 1,000 | $9.9K |
| May 21, 2026 | MICHEL GERARD J Director | Award | 16,965 | $0 |
| May 21, 2026 | Palasis Maria Director | Award | 16,965 | $0 |
| Mar 4, 2026 | Hopman Mark Chief Commercial Officer | Sale 10b5-1 plan | 353 | $4.1K |
| Mar 2, 2026 | Mensinger Mike Chief Product Officer | Sale | 1,064 | $13.2K |
| Mar 2, 2026 | Hopman Mark Chief Commercial Officer | Sale | 834 | $10.3K |
| Mar 2, 2026 | Russell Steven Jon Chief Medical Officer | Sale | 1,026 | $12.7K |
| Mar 2, 2026 | Saint Sean President & CEO | Sale | 3,384 | $41.8K |
| Mar 2, 2026 | Feider Stephen Chief Financial Officer | Sale | 1,428 | $17.7K |
| Feb 27, 2026 | Feider Stephen Chief Financial Officer | Award | 131,543 | $0 |
| Feb 27, 2026 | Mensinger Mike Chief Product Officer | Award | 109,105 | $0 |
| Feb 27, 2026 | Hopman Mark Chief Commercial Officer | Award | 109,105 | $0 |
| Feb 27, 2026 | Russell Steven Jon Chief Medical Officer | Award | 109,105 | $0 |
| Feb 27, 2026 | Saint Sean President & CEO | Award | 343,269 | $0 |
| Jan 13, 2026 | Lezack Adam Director | Award | 3,997 | $0 |
| Jan 13, 2026 | MICHEL GERARD J Director | Award | 3,997 | $0 |
| Jan 13, 2026 | Palasis Maria Director | Award | 3,997 | $0 |
| Jan 13, 2026 | Dearen Danny L. Director | Award | 3,997 | $0 |
| Jan 13, 2026 | CARNEY SEAN Director | Award | 3,997 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Beta Bionics, Inc.
Free account. Everything above stays public.
Write why you follow Beta Bionics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading